mapatumumab
immunoprobe
drozitumab
lexatumumab
tisotumab
acrixolimab
heterophile
pamrevlumab
tucotuzumab
agonistic monoclonal antibody
elotuzumab
intrabody
fontolizumab
sonepcizumab
Ab
bivatuzumab
-toxa-
lintuzumab
caplacizumab
samalizumab
matuzumab
tabalumab
antiantibody
antipolyvalent
immunocharacterize
immunopanning
carlumab
glembatumumab
intetumumab
onartuzumab
amlitelimab
evolocumab
ozoralizumab
nofetumomab
cixutumumab
ramucirumab
zanolimumab
polyclonal
antiustekinumab
adecatumumab
ozogamicin
reagin
cibisatamab
antisynthetase
antiphospholipid
presentation
antisubstance
antigenomic
volociximab
autocentromere